Isabelle Treilleux

Lyon, 69008, France

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 213 publications

[Corrigendum to: "French recommendations for clinical practice, Nice/Saint-Paul-de-Vence 2024-2025: Management of high-grade ovarian epithelial cancer" [Bull Cancer 2026;113:191-207]].

[Corrigendum to: "French recommendations for clinical practice, Nice/Saint-Paul-de-Vence 2024-2025: Management of high-grade ovarian epithelial cancer" [Bull Cancer 2026;113:191-207]].

Journal: Bulletin du cancer

Published: April 12, 2026

Ovarian central nervous system-type tumors: integrated neuropathological and methylation-based classification reveals site-related features.

Ovarian central nervous system-type tumors: integrated neuropathological and methylation-based classification reveals site-related features.

Journal: Acta neuropathologica communications

Published: February 22, 2026

Efficacy of buparlisib according to PIK3CA mutation status in recurrent or metastatic head and neck squamous cell carcinoma: A multicenter phase II trial.

Efficacy of buparlisib according to PIK3CA mutation status in recurrent or metastatic head and neck squamous cell carcinoma: A multicenter phase II trial.

Journal: Oral oncology

Published: February 20, 2026

Vascular and mesenchymal signatures of breast cancers associated with Yo and Ri paraneoplastic syndrome.

Vascular and mesenchymal signatures of breast cancers associated with Yo and Ri paraneoplastic syndrome.

Journal: Breast cancer research : BCR

Published: February 03, 2026

French recommendations for clinical practice, Nice/Saint-Paul-de-Vence 2024-2025: Management of high-grade ovarian epithelial cancer

French recommendations for clinical practice, Nice/Saint-Paul-de-Vence 2024-2025: Management of high-grade ovarian epithelial cancer

Journal: Bulletin du cancer

Published: October 23, 2025

HERV-derived epitopes represent new targets for T-cell-based immunotherapies in ovarian cancer.

HERV-derived epitopes represent new targets for T-cell-based immunotherapies in ovarian cancer.

Journal: Journal for immunotherapy of cancer

Published: July 15, 2025

Anti-AK5 limbic encephalitis in a patient with pleural mesothelioma.

Anti-AK5 limbic encephalitis in a patient with pleural mesothelioma.

Journal: Journal of neurology

Published: July 10, 2025

Molecular Relationship Between Ovarian Sertoli-Leydig Cell Tumors and Their Heterologous Elements: Emphasis on the Possible Prognostic Significance of TERT Pathogenic Variants.

Molecular Relationship Between Ovarian Sertoli-Leydig Cell Tumors and Their Heterologous Elements: Emphasis on the Possible Prognostic Significance of TERT Pathogenic Variants.

Journal: The American journal of surgical pathology

Published: May 28, 2025

Understanding biology to identify new therapeutic targets beyond chemotherapy in ovarian granulosa cell tumors

Understanding biology to identify new therapeutic targets beyond chemotherapy in ovarian granulosa cell tumors

Journal: Bulletin du cancer

Published: May 08, 2025

Clinical and tumor features of patients with immune checkpoint inhibitor-related neurological disorders and anti-Yo antibodies.

Clinical and tumor features of patients with immune checkpoint inhibitor-related neurological disorders and anti-Yo antibodies.

Journal: Therapeutic advances in neurological disorders

Published: May 05, 2025

Neoadjuvant immune checkpoint blockade before chemoradiation for cervical squamous carcinoma (GINECO window-of-opportunity COLIBRI study): a phase II trial.

Neoadjuvant immune checkpoint blockade before chemoradiation for cervical squamous carcinoma (GINECO window-of-opportunity COLIBRI study): a phase II trial.

Journal: Nature communications

Published: April 22, 2025

Tumor-stroma proportion on primary tumor as a prognostic biomarker in advanced ovarian cancer patients receiving chemo-immunotherapy as first-line therapy: analyses from the NeoPembrOV/GINECO phase II randomized trial.

Tumor-stroma proportion on primary tumor as a prognostic biomarker in advanced ovarian cancer patients receiving chemo-immunotherapy as first-line therapy: analyses from the NeoPembrOV/GINECO phase II randomized trial.

Journal: ESMO open

Published: February 12, 2025

Showing 1-12 of 213

Last Updated: 09/26/2026